JOP20210130A1 - مثبطات apol1 وطرق استخدامها - Google Patents

مثبطات apol1 وطرق استخدامها

Info

Publication number
JOP20210130A1
JOP20210130A1 JOP/2021/0130A JOP20210130A JOP20210130A1 JO P20210130 A1 JOP20210130 A1 JO P20210130A1 JO P20210130 A JOP20210130 A JO P20210130A JO P20210130 A1 JOP20210130 A1 JO P20210130A1
Authority
JO
Jordan
Prior art keywords
same
methods
apol1
inhibitors
ndkd
Prior art date
Application number
JOP/2021/0130A
Other languages
English (en)
Inventor
Yi Shi
Ales Medek
Michael Brodney
Leslie A Dakin
Warren A Dorsch
Francois Denis
Peter Rose
Timothy J Senter
Muna Shrestha
Camil Sayegh
Kevin Gagnon
Anne Fortier
Jingrong Cao
Elaine B Krueger
Jon H Come
Brian Ledford
Suganthini S Nanthakumar
Olivier Nicolas
Martine Hamel
Kan-Nian Hu
Tiansheng Wang
Faith Witkos
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of JOP20210130A1 publication Critical patent/JOP20210130A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C07F7/0814—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring is substituted at a C ring atom by Si
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C07F7/0816—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring comprising Si as a ring atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/46—Phosphinous acids R2=P—OH; Thiophosphinous acids; Aminophosphines R2-P-NH2 including R2P(=O)H; derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

غير متوفر
JOP/2021/0130A 2018-12-17 2019-12-17 مثبطات apol1 وطرق استخدامها JOP20210130A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862780667P 2018-12-17 2018-12-17
PCT/US2019/066746 WO2020131807A1 (en) 2018-12-17 2019-12-17 Inhibitors of apol1 and methods of using same

Publications (1)

Publication Number Publication Date
JOP20210130A1 true JOP20210130A1 (ar) 2023-01-30

Family

ID=69182627

Family Applications (3)

Application Number Title Priority Date Filing Date
JOP/2021/0130A JOP20210130A1 (ar) 2018-12-17 2019-12-17 مثبطات apol1 وطرق استخدامها
JOP/2021/0131A JOP20210131A1 (ar) 2018-12-17 2019-12-17 مثبطات apol1 وطرق استخدامها
JOP/2021/0129A JOP20210129A1 (ar) 2018-12-17 2019-12-17 مثبطات apol1 وطرق استخدامها

Family Applications After (2)

Application Number Title Priority Date Filing Date
JOP/2021/0131A JOP20210131A1 (ar) 2018-12-17 2019-12-17 مثبطات apol1 وطرق استخدامها
JOP/2021/0129A JOP20210129A1 (ar) 2018-12-17 2019-12-17 مثبطات apol1 وطرق استخدامها

Country Status (23)

Country Link
US (2) US11618746B2 (ar)
EP (1) EP3897833A1 (ar)
JP (1) JP2022515369A (ar)
KR (1) KR20210116483A (ar)
CN (1) CN113453760A (ar)
AR (1) AR116913A1 (ar)
AU (1) AU2019405477A1 (ar)
BR (1) BR112021011564A2 (ar)
CA (1) CA3121910A1 (ar)
CL (1) CL2021001561A1 (ar)
CO (1) CO2021009053A2 (ar)
CR (1) CR20210383A (ar)
DO (1) DOP2021000116A (ar)
EC (1) ECSP21052184A (ar)
IL (1) IL283592A (ar)
JO (3) JOP20210130A1 (ar)
MA (1) MA54538A (ar)
MX (1) MX2021007152A (ar)
PE (1) PE20212302A1 (ar)
SG (1) SG11202105769XA (ar)
TW (1) TW202039471A (ar)
UY (1) UY38514A (ar)
WO (1) WO2020131807A1 (ar)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3121910A1 (en) 2018-12-17 2020-06-25 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
EP4097083A1 (en) * 2020-01-29 2022-12-07 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
WO2021158666A1 (en) * 2020-02-04 2021-08-12 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitor and methods of using same
WO2021178768A1 (en) * 2020-03-06 2021-09-10 Vertex Pharmaceuticals Incorporated Methods of treating apol-1 dependent focal segmental glomerulosclerosis
EP4204423A1 (en) * 2020-08-26 2023-07-05 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
US20230119114A1 (en) * 2021-08-26 2023-04-20 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitors and methods of using same
WO2023101981A1 (en) * 2021-11-30 2023-06-08 Vertex Pharmaceuticals Incorporated Spirocyclic inhibitors of apol1 and methods of using same
WO2023154344A1 (en) * 2022-02-08 2023-08-17 Vertex Pharmaceuticals Incorporated 2-methyl-4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] derivatives as inhibitors of apol1 and methods of using same
WO2023194895A1 (en) 2022-04-06 2023-10-12 Glaxosmithkline Intellectual Property Development Limited Pyrrol derivatives as inhibitors of apolipoprotein l-1
WO2024040235A1 (en) * 2022-08-19 2024-02-22 Maze Therapeutics, Inc. Apol1 inhibitors and methods of use

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2801585B1 (fr) 1999-11-25 2002-02-15 Fournier Ind & Sante Nouveaux antagonistes des recepteurs de l'ii-8
EP1324985A4 (en) 2000-10-02 2004-10-06 Merck & Co Inc PRENYL PROTEIN TRANSFERASE INHIBITORS
FR2824827B1 (fr) 2001-05-17 2004-02-13 Fournier Lab Sa Nouveaux derives de 5-phenyl-1h-indole antagoniste des recepteurs de l'interleukine-8
FR2824826B1 (fr) 2001-05-17 2003-11-07 Fournier Lab Sa Nouveaux derives de 5-cyano-1h-indole antagonistes des recepteurs de l'interleukine-8
JP2006504618A (ja) 2001-11-14 2006-02-09 テバ ファーマシューティカル インダストリーズ リミティド 非結晶性及び結晶性ロサルタン・カリウム、及びそれらの調製方法
WO2003104180A1 (en) 2002-06-05 2003-12-18 Natco Pharma Limited Process for the preparation of 4-(4-fluorobenzoyl) butyric acid
JP5236664B2 (ja) 2007-02-01 2013-07-17 レスバーロジックス コーポレイション 心血管疾患を予防および治療するための化合物
US8436038B2 (en) 2007-08-17 2013-05-07 Lg Life Sciences Ltd. Indole and indazole compounds as an inhibitor of cellular necrosis
JP5685203B2 (ja) 2009-05-29 2015-03-18 ラクオリア創薬株式会社 カルシウムチャネル遮断薬またはナトリウムチャネル遮断薬としてのアリール置換カルボキサミド誘導体
WO2014085154A1 (en) 2012-11-27 2014-06-05 Beth Israel Deaconess Medical Center, Inc. Methods for treating renal disease
WO2015048301A1 (en) * 2013-09-26 2015-04-02 Pharmakea, Inc. Autotaxin inhibitor compounds
US10377711B2 (en) 2014-08-27 2019-08-13 The University Court Of The University Of Aberdeen Cannabinoid type 1 receptor modulators
DK3204380T3 (da) 2014-10-08 2019-11-04 Inst Nat Sante Rech Med Hidtil ukendte aminopyridinforbindelser, der er anvendelige som hæmmere af proteinprenylering
JP6804524B2 (ja) 2015-08-27 2020-12-23 ファイザー・インク Ｉｒａｋ４モジュレーターとしての二環式縮合ヘテロアリールまたはアリール化合物
CA3121910A1 (en) 2018-12-17 2020-06-25 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
EP4097083A1 (en) 2020-01-29 2022-12-07 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
WO2021158666A1 (en) 2020-02-04 2021-08-12 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitor and methods of using same
WO2021178768A1 (en) 2020-03-06 2021-09-10 Vertex Pharmaceuticals Incorporated Methods of treating apol-1 dependent focal segmental glomerulosclerosis
JP2023530271A (ja) 2020-06-12 2023-07-14 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｐｏｌ１の阻害剤及びこれを使用する方法
US20230250087A1 (en) 2020-06-12 2023-08-10 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitor and methods of using same
US20230014907A1 (en) 2020-06-12 2023-01-19 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
EP4204423A1 (en) 2020-08-26 2023-07-05 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same

Also Published As

Publication number Publication date
ECSP21052184A (es) 2021-08-31
AR116913A1 (es) 2021-06-23
IL283592A (en) 2021-07-29
PE20212302A1 (es) 2021-12-10
US11618746B2 (en) 2023-04-04
BR112021011564A2 (pt) 2021-08-31
WO2020131807A1 (en) 2020-06-25
CR20210383A (es) 2021-09-22
MX2021007152A (es) 2021-11-03
SG11202105769XA (en) 2021-07-29
JP2022515369A (ja) 2022-02-18
US20200377479A1 (en) 2020-12-03
KR20210116483A (ko) 2021-09-27
US20230271945A1 (en) 2023-08-31
CA3121910A1 (en) 2020-06-25
UY38514A (es) 2020-07-31
CN113453760A (zh) 2021-09-28
CL2021001561A1 (es) 2021-11-26
AU2019405477A1 (en) 2021-06-24
MA54538A (fr) 2021-10-27
DOP2021000116A (es) 2021-09-30
CO2021009053A2 (es) 2021-08-09
JOP20210129A1 (ar) 2023-01-30
JOP20210131A1 (ar) 2023-01-30
EP3897833A1 (en) 2021-10-27
TW202039471A (zh) 2020-11-01

Similar Documents

Publication Publication Date Title
CR20210383A (es) Inhibidores de apol 1 y sus métodos de uso
CR20200347A (es) Inhibidores pd-1/pd-l1
CR20200376A (es) Inhibidores de cd73
CR20200520A (es) Compuestos heterocíclicos como inmunomoduladores
CO2021005884A2 (es) Moduladores de la alfa-1 antitripsina
EA201891268A1 (ru) Соединения, которые можно применять в качестве ингибиторов киназы
EA202191084A1 (ru) Соединения пиридазинонов и их применения
GEP20227443B (en) Magl inhibitors
MX2021005348A (es) Compuestos de piridazinonas y usos de los mismos.
EA202092086A1 (ru) Ингибиторы аргиназы
PH12021500008A1 (en) Transglutaminase 2 (tg2) inhibitors
MX2021003187A (es) Inhibición de la peptidasa específica de ubiquitina 9x.
MX2023002269A (es) Inhibidores de apol1 y metodos para usar los mismos.
MX2022007841A (es) Degradadores del regulador dependiente de actina asociado a la matriz relacionado con el complejo switch/sacarosa no fermentable de la subfamilia a de la cromatina (smarca)y usos de los mismos.
ECSP20082339A (es) Moduladores de la expresión de apol1
EA202090424A1 (ru) Бициклические ингибиторы гистондеацетилазы
CL2022001452A1 (es) Inhibidores de masp-2 y métodos de uso.
MX2020011826A (es) Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas.
MX2021010603A (es) Inhibidores de caspasa y metodos de uso de los mismos.
MX2022006312A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.
JOP20210143A1 (ar) تركيبات وطرق لعلاج ومنع التصلب الجانبي الضموري
EA202191058A1 (ru) Антитела против муцина-16 и способы их применения
WO2020102243A3 (en) In-flow photooxygenation of aminothienopyridinones generates novel ptp4a3 phosphatase inhibitors
EA202190766A1 (ru) Иммуномодуляторы, их композиции и способы применения
EA202290061A1 (ru) Ингибиторы аутофагии на основе аминопиримидинамида и способы их применения